Chronic PainHeadache Disorders (Cluster & Migraine)LSDPsilocybin

Response of cluster headache to psilocybin and LSD

This qualitative interview study (n=53) assessed the efficacy of psilocybin and LSD to treat cluster headaches and found that a single dose was often sufficient to terminate a cluster period and that subhallucinogenic doses were also often reported to be effective treatments.

Authors

  • James Halpern
  • Andrew Sewell

Published

Neurology
individual Study

Abstract

Introduction

Cluster headache, often considered the most painful of all types of headache,1 affects predominantly men (0.4% vs 0.08% of women) and typically begins after age 20 years. No medications are known to terminate cluster periods or extend remission periods. The effects of the ergot alkaloid derivative lysergic acid diethylamide (LSD) and the related indolalkylamine psilocybin on cluster headache have not previously been described and may include such properties.

Methods

The authors interviewed 53 cluster headache patients who had used psilocybin or lysergic acid diethylamide (LSD) to treat their condition.

Results

Twenty-two of 26 psilocybin users reported that psilocybin aborted attacks; 25 of 48 psilocybin users and 7 of 8 LSD users reported cluster period termination; 18 of 19 psilocybin users and 4 of 5 LSD users reported remission period extension.

Discussion

Research on the effects of psilocybin and LSD on cluster headache may be warranted.

Available with Blossom Pro

Research Summary of 'Response of cluster headache to psilocybin and LSD'

Introduction

Cluster headache is described as an intensely painful primary headache disorder that predominantly affects men and typically begins after age 20. The condition occurs in episodic and chronic forms: episodic cluster headache arises in discrete periods of attacks separated by pain-free remissions, whereas chronic cluster headache features attacks continuing for more than one year without remissions longer than one month. Acute treatments such as high-flow oxygen and subcutaneous sumatriptan are standard for aborting individual attacks, and prophylactic agents including verapamil, lithium and corticosteroids are used to suppress attacks during cluster periods. However, no medications had been reported to reliably terminate an ongoing cluster period or to extend remission periods prior to this study. Sewell and colleagues report a case-series investigation prompted by a patient’s account that recreational use of LSD and later psilocybin produced lasting remissions of his episodic cluster periods. The study aimed to characterise the experiences of people with cluster headache who had used psilocybin-containing mushrooms or LSD specifically to treat their condition, focusing on three outcomes: aborting individual attacks, terminating cluster periods, and extending remission periods. The investigators collected structured self-reports from a sample of confirmed cluster headache patients to explore whether these substances showed signals of efficacy that might merit further research.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

Cited By (66)

Papers in Blossom that reference this study

Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action

Cameron, L. P., Benetatos, J., Lewis, V. et al. · Journal of Neuroscience (2023)

45 cited
Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study

Cavarra, M., Mason, N. L., Kuypers, K. P. C. et al. · European Journal of Pain (2023)

The Potential of Psychedelics for the Treatment of Episodic Migraine

Schindler, E. A. D. · Current Pain and Headache Reports (2023)

A non-hallucinogenic LSD analog with therapeutic potential for mood disorders

Lewis, V., Bonniwell, E. M., Lanham, J. K. et al. · Cell Reports (2023)

102 cited
Views on Using Psychoactive Substances to Self-Manage Functional Neurological Disorder: Online Patient Survey Results

Butler, M., Seynaeve, M., Bao, J. et al. · Journal of Clinical Psychiatry and Clinical Neuroscience (2023)

4 cited
Show all 66 papers
Therapeutic use of psilocybin: Practical considerations for dosing and administration

MacCallum, C. A., Pistawka, C. A., Deol, J. K. et al. · Frontiers in Psychiatry (2022)

Default Mode Network Modulation by Psychedelics: A Systematic Review

Gattuso, J. J., Perkins, D., Ruffell, S. G. D. et al. · International Journal of Neuropsychopharmacology (2022)

Microdosing psilocybin for chronic pain: a case series

Lyes, M., Yang, K. H., Castellanos, J. P. et al. · PAIN (2022)

Self-Reported Efficacy of Treatments in Cluster Headache: a Systematic Review of Survey Studies

Rusanen, S. S., Schindler, E. A. D., Artto, V. A. et al. · Current Pain and Headache Reports (2022)

Psychedelic Cognition-The Unreached Frontier of Psychedelic Science

Balaet, M. · Frontiers in Neuroscience (2022)

Psilocybin Combines Rapid Synaptogenic And Anti-Inflammatory Effects In Vitro

Smedfors, G., Glotfelty, E., Papatziamos, C. et al. · Research Square (2022)

Beating Pain with Psychedelics: Matter over Mind?

Elman, I., Borsook, D., Pustilink, A. · Neuroscience and Biobehavioral Reviews (2022)

Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia

Glynos, N. G., Pierce, J., Davis, A. K. et al. · Journal of Psychoactive Drugs (2022)

Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin

Schindler, E. A. D., Sewell, R. A., Gottschalk, C. H. et al. · Neurotherapeutics (2021)

The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant Action

Dudysová, D., Janků, K., Šmotek, M. et al. · Frontiers in Pharmacology (2020)

25 cited
Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants

Zhang, D. Z., Holze, F., Liechti, M. E. et al. · Clinical Pharmacology and Therapeutics (2020)

49 cited
Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor

Kim, K., Che, T., Panova, O. et al. · Cell (2020)

380 cited
A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers

Ramaekers, J. G., Hutten, N. P. W., Mason, N. L. et al. · Journal of Psychopharmacology (2020)

74 cited
Chronic pain and psychedelics: a review and proposed mechanism of action

Castellanos, J. P., Woolley, C., Bruno, K. A. et al. · Regional Anesthesia and Pain Medicine (2020)

101 cited
Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials

Fuentes, J. J., Fonseca, F., Elices, M. et al. · Frontiers in Psychiatry (2020)

Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function

Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)

Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions

Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)

Increased use of illicit drugs in a Dutch cluster headache population

De Coo, I. F., Naber, W. C., Wilbrink, L. A. et al. · Cephalalgia (2018)

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act

Johnson, M. W., Griffiths, R. R., Hendricks, P. S. et al. · Neuropharmacology (2018)

Ceremonial ‘Plant Medicine’ use and its relationship to recreational drug use: an exploratory study

Dorsen, C., Palamar, J., Shedlin, M. G. · Addiction Research and Theory (2018)

21 cited
Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics

Schindler, E. A. D., Wallace, R. M., Sloshower, J. A. et al. · Frontiers in Pharmacology (2018)

Psychedelics: Where we are now, why we got here, what we must do

Belouin, S. J., Henningfield, J. E. · Neuropharmacology (2018)

Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review

Reiche, S., Hermle, L., Gutwinski, S. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018)

Potential Therapeutic Effects of Psilocybin

Johnson, M. W., Griffiths, R. R. · Neurotherapeutics (2017)

Crystal Structure of an LSD-Bound Human Serotonin Receptor

Wacker, D., Wang, S., Mccorvy, J. D. et al. · Cell (2017)

Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways

López-Giménez, J. F., González-Maeso, J. · Current Topics in Behavioral Neurosciences (2017)

211 cited
Phenomenology, Structure, and Dynamic of Psychedelic States

Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)

Psychedelics in the treatment of unipolar mood disorders: a systematic review

Rucker, J., Young, A. H., Jelen, L. A. et al. · Journal of Psychopharmacology (2016)

Clinical Applications of Hallucinogens: A Review

Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)

174 cited
Treating Addiction: Perspectives from EEG and Imaging Studies on Psychedelics

Tófoli, L. F., De Araujo, D. B. · International Review of Neurobiology (2016)

A Public-Health-Based Vision for the Management and Regulation of Psychedelics

Haden, M., Emerson, B., Tupper, K. W. · Journal of Psychoactive Drugs (2016)

28 cited
Psychedelics

Nichols, D. E. · Pharmacological Reviews (2016)

Lysergic acid diethylamide: a drug of ‘use’?

Das, S., Barnwal, P., Ramasamy, A. et al. · Therapeutic Advances in Psychopharmacology (2016)

New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca

McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)

Serotonergic Hallucinogen-Induced Visual Perceptual Alterations

Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)

Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey

Schindler, E. A. D., Gottschalk, C. H., Weil, M. J. et al. · Journal of Psychoactive Drugs (2015)

91 cited
Acute effects of lysergic acid diethylamide in healthy subjects

Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)

50 cited
Psilocybin - Summary of knowledge and new perspectives

Tylš, F., Páleníček, T., Horacek, J. · European Neuropsychopharmacology (2013)

Effects of Schedule I drug laws on neuroscience research and treatment innovation

King, C., Nichols, D. E. · Nature Reviews Neuroscience (2013)

Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers

Johnson, M. W., Sewell, R. A., Griffiths, R. R. · Drug and Alcohol Dependence (2012)

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)

The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)

User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study

Carhart-Harris, R. L., Nutt, D. J. · Journal of Substance Use (2010)

The pharmacology of lysergic acid diethylamide: a review

Passie, T., Halpern, J. H., Stichtenoth, D. O. et al. · CNS Neuroscience and Therapeutics (2008)

Unauthorized Research on Cluster Headache

Sewell, R. A. · Preprints (2008)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.